Amgen's AMG-162 for treatment of osteoporosis will become a blockbuster by 2013

Decision Resources, Inc., forecasts that Amgen's novel biological agent for the treatment of osteoporosis, AMG-162, will become a blockbuster by 2013. Premium pricing of AMG-162 will propel the sales of this agent.

Continue to Amgen's AMG-162 for treatment of osteoporosis will become a blockbuster by 2013 on News-Medical News Feed.

Medical Buzz delivers the most recent headlines from the medical world. Diseases, cures, accidents, medicin. Click below for more headlines ...
Medical buzz